GlaxoSmithKline Will Buy Arixtra, Fraxiparine In Event Of Sanofi/Aventis Merger
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK would pay $541 mil. for the two anti-thrombotic agents and a manufacturing facility in France. The sale represents a preemptive divestiture on Sanofi's part; both products compete with Aventis' Lovenox.
You may also be interested in...
GSK’s Arixtra Acute Coronary Syndrome Indication Gets Priority Review
Supplemental indication for the anticoagulant has a Jan. 31 user fee date.
GSK’s Arixtra Acute Coronary Syndrome Indication Gets Priority Review
Supplemental indication for the anticoagulant has a Jan. 31 user fee date.
Aventis' $200 Mil. Merger Defense Costs Will Be Absorbed By Sanofi
Sanofi will absorb €156 mil. ($207 mil.) in Aventis' merger-related costs in 2004, the company disclosed during its 2004 earnings call March 1